Zacks Investment Research upgraded shares of NewLink Genetics (NASDAQ:NLNK) from a hold rating to a buy rating in a report issued on Saturday, Zacks.com reports. Zacks Investment Research currently has $2.00 price objective on the biotechnology company’s stock.
According to Zacks, “NewLink Genetics Corporation is a biopharmaceutical company which focuses on discovering, developing and commercializing immunotherapeutic products for cancer treatment. Its portfolio also includes biologic and small-molecule immunotherapy products used for the treatment of oncology indications. NewLink Genetics Corporation is headquartered in Ames, Iowa. “
Separately, ValuEngine raised shares of NewLink Genetics from a sell rating to a hold rating in a report on Thursday.
NewLink Genetics (NASDAQ:NLNK) last posted its quarterly earnings data on Tuesday, July 30th. The biotechnology company reported ($0.27) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.29) by $0.02. The firm had revenue of $0.15 million for the quarter. NewLink Genetics had a negative net margin of 6,587.56% and a negative return on equity of 33.23%. On average, analysts predict that NewLink Genetics will post -0.03 earnings per share for the current fiscal year.
A number of institutional investors and hedge funds have recently bought and sold shares of NLNK. Pennsylvania Trust Co purchased a new position in NewLink Genetics during the 1st quarter worth $48,000. Virtu Financial LLC purchased a new position in NewLink Genetics during the 1st quarter worth $60,000. Two Sigma Advisers LP boosted its holdings in NewLink Genetics by 22.6% during the 4th quarter. Two Sigma Advisers LP now owns 110,000 shares of the biotechnology company’s stock worth $167,000 after acquiring an additional 20,300 shares during the last quarter. Bank of New York Mellon Corp boosted its holdings in shares of NewLink Genetics by 20.8% in the 4th quarter. Bank of New York Mellon Corp now owns 145,832 shares of the biotechnology company’s stock worth $222,000 after buying an additional 25,084 shares during the last quarter. Finally, Dimensional Fund Advisors LP boosted its holdings in shares of NewLink Genetics by 31.3% in the 4th quarter. Dimensional Fund Advisors LP now owns 375,866 shares of the biotechnology company’s stock worth $571,000 after buying an additional 89,528 shares during the last quarter. 34.14% of the stock is currently owned by hedge funds and other institutional investors.
NewLink Genetics Company Profile
NewLink Genetics Corporation, a late clinical-stage immuno-oncology company, focuses on discovering and developing novel immunotherapeutic products for the treatment of patients with cancer. It is developing Indoximod, an indoleamine-2, 3-dioxygenase (IDO) pathway inhibitor that is in clinical development in combination with other cancer therapeutics for patients with diffuse intrinsic pontine glioma, pediatric brain tumors, acute myeloid leukemia, and melanoma.
Featured Story: Does the Step Transaction Doctrine Affect a Backdoor Roth IRA?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for NewLink Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NewLink Genetics and related companies with MarketBeat.com's FREE daily email newsletter.